Caltech/UCLA Individualized Theranostic Engineering to Advance Metabolic System (iTEAM)

摘要 加州理工学院(Caltech)和加州大学洛杉矶分校(UCLA) 合作将高级成像和传感与翻译所需的计算相结合 应对全球心脏代谢性疾病的技术创新。加州大学洛杉矶分校/加州理工学院整合 推进新陈代谢医学的鼻咽癌工程(ITEAM)计划代表了一种新的范式， 将被正式化为为期两年的结构化课程，重点是招聘代表不足的人 博士后工程师或物理学家在学术界和工业界担任领导职务。这个 加州理工大学的基本优势和加州大学洛杉矶分校的临床优势的融合有利于 在1)高级传感或2)结合计算的成像方面进行个性化培训，以解决3) 心脏代谢疾病。ITEAM计划正在与行业领先者(安进、强生和 约翰逊、美敦力和爱德华兹生命科学学院)提供实习、指导和领导力课程。这两个 加州理工学院多样性中心和加州大学洛杉矶分校教师多样性与发展办公室支持举办关于 科学、技术、工程和数学(STEM)，面向妇女和代表不足的少数群体。至 为了实施加州大学洛杉矶分校/加州理工学院的这一项目，我们在 包括21名主要和联合导师、13名咨询导师和10名行业领导者(42%为女性)。 每位Iteam学者将有共同导师关系：一位来自支持技术的主要导师，一位次要导师 来自心脏新陈代谢医学和/或工业。在第一年，ITEAM学者将：1)参加最初的两个- 包括导师、计划负责人、临床医生、医生-科学家和行业领导者在内的日间研讨会 探索项目、期望、指导和目标；2)与项目总监(S)一对一会面，以 最终确定主要导师(成像或传感)和共同导师(心脏代谢性疾病或行业)；3)制定 与咨询和培训委员会一起制定个性化发展计划(IDP)，以最终确定项目；以及4) 加强高级成像、传感器或计算方面的基础知识，并对 生物医学研究和出版中的伦理问题。在第二年，Iteam学者将有机会1) 在与主要导师和联合导师的季度会议上介绍正在进行的工作并提供反馈 导师，2)参加临床和转化研究路径证书的选项 加州大学洛杉矶分校临床翻译科学研究所(CTSI)或FDA监管科学的法律和技术 (BE188/299)；和/或3)参加加州大学洛杉矶分校CTSI赞助的专业发展，为 学术或行业职业。加州理工学院和加州大学洛杉矶分校的院长都承诺为每个项目提供匹配的资金 学者。加州大学洛杉矶分校负责研究生教育的副教务长，并承诺为学员提供补充支持 增强学员的多样性。总体而言，这一计划为科学工作者注入了下一代 生物工程师准备解决全球心脏代谢性疾病的威胁。

ABSTRACT The California Institute of Technology (Caltech) and the University of California at Los Angeles (UCLA) have partnered to integrate advanced imaging and sensing coupled with computing needed to translate technological innovation to address the global cardiometabolic disease. The UCLA/Caltech integrated Theranostic Engineering to Advance Metabolic Medicine (iTEAM) Program represents a new paradigm that will be formalized into a 2-year, structured curriculum with an emphasis on recruiting the under-represented post-doctoral engineers or physical scientists into leadership roles in academia and industry. The convergence of the fundamental strengths of Caltech and clinical strengths of UCLA is conducive to individualize training in 1) advanced sensing or 2) imaging coupled with computing to address 3) cardiometabolic disease. The iTEAM program is partnering with industry leaders (Amgen, Johnson & Johnson, Medtronic, and Edwards Lifesciences) for internship, mentorship, and leadership programs. Both the Caltech Diversity Center and UCLA Faculty Diversity & Development Office have supported workshops on Science Technology Engineering & Mathematics (STEM) for women and underrepresented minorities. To implement this UCLA/Caltech iTEAM program, we have developed a mentoring and self-evaluating structure in the inclusion of 21 primary and co-mentors, 13 consulting mentors, and 10 industry leaders (42% female). Each iTEAM scholar will have co-mentorships: a primary mentor from enabling technologies and a secondary from cardiometabolic medicine and/or industry. In Year 1, iTEAM scholars will: 1) Participate in an initial two- day workshop including mentors, program leaders, clinicians, physician-scientists, and industry leaders to explore projects, expectations, mentorship, and goals; 2) Meet one-to-one with the Program Director(s) to finalize a primary (imaging or sensing) and a co-mentor (cardiometabolic disease or industry); 3) Develop an Individualized Development Plans (IDP) with the Advising & Training Committee to finalize the project; and 4) Strengthen fundamental knowledge in advanced imaging, sensors, or computation and didactic training for ethics in biomedical research and publications. In Year 2, iTEAM scholars will be afforded 1) the opportunity to present work-in-progress and provide feedback in quarterly meetings with a primary mentor and with a co- mentor, 2) an option to participate in a certificate in Pathways in Clinical and Translational Research from the UCLA Clinical Translational Science Institute (CTSI) or Law and Technology for FDA regulatory science (BE188/299); and/or 3) to participate in UCLA CTSI-sponsored professional development in preparation for an academic or industry career. Both Caltech and UCLA Deans have committed matching funds for each iTEAM scholar. UCLA Vice Provost for Graduate Education and has also committed supplemental trainee support to enhance the diversity of trainees. Overall, this program infuses the scientific workforce with the next generation of theranostic bioengineers prepared to solve the worldwide threat of cardiometabolic disease.